Replimune Group (NASDAQ:REPL) Shares Down 6.4% – What’s Next?

Replimune Group, Inc. (NASDAQ:REPL)’s share price traded down 6.4% during mid-day trading on Friday . The company traded as low as $9.14 and last traded at $9.0950. 271,661 shares were traded during mid-day trading, a decline of 79% from the average session volume of 1,289,014 shares. The stock had previously closed at $9.72.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Wedbush upgraded Replimune Group from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $4.00 to $18.00 in a research note on Monday, October 20th. Leerink Partners upgraded shares of Replimune Group from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $3.00 to $13.00 in a report on Monday, October 20th. HC Wainwright raised shares of Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Monday, October 27th. JPMorgan Chase & Co. upgraded shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price objective for the company in a research note on Monday, October 20th. Finally, Piper Sandler upgraded shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price objective on the stock in a research note on Monday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.75.

Replimune Group Trading Down 8.8%

The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.26. The company has a fifty day moving average price of $9.61 and a two-hundred day moving average price of $7.65. The firm has a market capitalization of $695.37 million, a price-to-earnings ratio of -2.57 and a beta of 0.72.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.03). As a group, research analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Insider Transactions at Replimune Group

In related news, CEO Sushil Patel sold 10,000 shares of the stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $11.13, for a total transaction of $111,300.00. Following the transaction, the chief executive officer owned 333,576 shares of the company’s stock, valued at approximately $3,712,700.88. This represents a 2.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christopher Sarchi sold 5,208 shares of Replimune Group stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $9.10, for a total transaction of $47,392.80. Following the completion of the transaction, the insider owned 123,088 shares of the company’s stock, valued at $1,120,100.80. This trade represents a 4.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 25,625 shares of company stock worth $257,607 in the last ninety days. 5.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Replimune Group

Several hedge funds and other institutional investors have recently made changes to their positions in REPL. Goldman Sachs Group Inc. lifted its holdings in Replimune Group by 20.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock worth $6,729,000 after buying an additional 119,145 shares during the last quarter. Exome Asset Management LLC lifted its stake in Replimune Group by 438.6% during the first quarter. Exome Asset Management LLC now owns 294,846 shares of the company’s stock worth $2,875,000 after purchasing an additional 240,108 shares during the last quarter. Saturn V Capital Management LP purchased a new stake in Replimune Group during the second quarter worth approximately $1,198,000. Squarepoint Ops LLC boosted its holdings in Replimune Group by 394.0% in the second quarter. Squarepoint Ops LLC now owns 67,929 shares of the company’s stock valued at $631,000 after purchasing an additional 54,178 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in Replimune Group in the second quarter valued at approximately $403,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.